4D Molecular Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
4D Molecular Therapeutics, Inc. (FDMT) had Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant of 3.18 million shares as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant · last filed 2023-11-09
- 2023-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 3.18M shares.
- 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 2.90M shares.
- 2023-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 2.81M shares.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 2.11M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant |
|---|---|
| 2023-09-30 | 3.18M shares 10-Q · filed 2023-11-09 |
| 2023-06-30 | 2.90M shares 10-Q · filed 2023-08-09 |
| 2023-03-31 | 2.81M shares 10-Q · filed 2023-05-11 |
| 2022-12-31 | 2.11M shares 10-Q · filed 2023-11-09 |
| 2022-09-30 | 2.04M shares 10-Q · filed 2022-11-08 |
| 2022-06-30 | 3.07M shares 10-Q · filed 2022-08-11 |
| 2022-03-31 | 3.31M shares 10-Q · filed 2022-05-12 |
| 2021-12-31 | 2.69M shares 10-K · filed 2023-03-15 |
| 2021-09-30 | 2.61M shares 10-Q · filed 2021-11-10 |
| 2021-06-30 | 2.73M shares 10-Q · filed 2021-08-12 |
| 2021-03-31 | 3.16M shares 10-Q · filed 2021-05-13 |
| 2020-12-31 | 2.61M shares 10-K · filed 2022-03-28 |
| 2019-12-31 | 125.35K shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |